专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007059461A3 ADENOVIRAL VECTOR-BASED FOOT-AND-MOUTH DISEASE VACCINE 审中-公开
标题翻译：基于腺病毒的足球疫苗疫苗
公开(公告)号：WO2007059461A3
公开(公告)日：2007-08-02
申请号：PCT/US2006060830
申请日：2006-11-13
申请人： GENVEC INC , BROUGH DOUGLAS E , BRUDER JOSEPH T , KING C RICHTER
发明人： BROUGH DOUGLAS E , BRUDER JOSEPH T , KING C RICHTER
IPC分类号： A61K39/135 , C12N15/861
CPC分类号： A61K39/135 , A61K39/12 , A61K2039/5258 , A61K2039/552 , C12N15/86 , C12N2710/10343 , C12N2770/32134 , C12N2770/32171
摘要： The invention is directed to an adenoviral vector comprising at least one nucleic acid sequence encoding an aphthovirus antigen and/or a cytokine operably linked to a promoter. The adenoviral vector is replication-deficient and requires at most complementation of both the E1 region and the E4 region of the adenoviral genome for propagation. The invention also is directed to a method of inducing an immune response in a mammal comprising administering to the mammal a composition comprising the aforementioned adenoviral vector.
摘要翻译：本发明涉及一种腺病毒载体，其包含至少一个编码与促进剂可操作地连接的aphthovirus抗原和/或细胞因子的核酸序列。腺病毒载体是复制缺陷型的，需要对腺病毒基因组的E1区域和E4区域的最多互补进行扩增。本发明还涉及在哺乳动物中诱导免疫应答的方法，其包括向哺乳动物施用包含上述腺病毒载体的组合物。

2. 发明申请

WO2012003129A3 DEVELOPMENT OF A MARKER FOOT AND MOUTH DISEASE VIRUS VACCINE CANDIDATE THAT IS ATTENUATED IN THE NATURAL HOST 审中-公开
标题翻译：发展自然生物和自然病毒的病毒疫苗病毒候选人的发展
公开(公告)号：WO2012003129A3
公开(公告)日：2012-07-05
申请号：PCT/US2011041567
申请日：2011-06-23
申请人： US AGRICULTURE , RIEDER AIDA E , RODRIGUEZ LUIS L , HOLLISTER JASON R , UDDOWLA SABENA
发明人： RIEDER AIDA E , RODRIGUEZ LUIS L , HOLLISTER JASON R , UDDOWLA SABENA
IPC分类号： C12N15/42 , A61K39/135 , C12N15/86 , C12Q1/70
CPC分类号： C07K14/005 , A61K39/12 , A61K39/135 , A61K2039/5252 , A61K2039/5254 , A61K2039/552 , A61K2039/55566 , C12N7/00 , C12N2770/32121 , C12N2770/32122 , C12N2770/32134 , C12N2770/32151 , C12N2770/32162 , C12N2770/32163 , C12N2770/32171 , C12Q1/701 , G01N33/56983 , G01N2469/10
摘要： We have generated novel molecularly marked FMDV A24LL3DYR and A24LL3BPVKV3DYR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3Dpol and 3B proteins. Mutations were introduced into MAb F32-44 epitope in FMDV A24Cruzeiro spanning residues H27N31 in 3Dpol protein to obtain the homologous amino acid sequence of bovine rhinitis virus type B (BRV-2, Y27R31). Mutations in 3B consisted of a deletion of 3B1 and a mutation in 3B2 (RQKP->PVKV, found in BRV-2) that abolishes reactivity with MAb F8B. These attenuated marker viruses provide safe alternatives for FMD vaccine manufacturing. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. Chimeric viruses were produced to contain the capsid of distantly related type A/Turkey/06 or Asia type FMDV: Asia1-A24LL3BPVKV3DYR and A/Turkey/06 -A24LL3BPVKV3DYR. A24LL3DYR and A24LL3BPVKV3DYR mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A24LL3DYR or the chimeric A-Turkey/06-A24LL3BPVKV3DYR or Asia1-A24LL3BPVKV3DYR viruses. Cattle immunized with chemically inactivated A24LL3DYR and A24LL3BPVKV3DYRvaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine and protected 100% the animals from challenge with parental virus. The single and double marked-FMDV vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.
摘要翻译：我们生成了新型分子标记的FMDV A24LL3DYR和A24LL3BPVKV3DYR疫苗候选物。突变体病毒包含导致体内减毒的前导编码区（LL）的缺失和引入病毒非结构3Dpol和3B蛋白之一或两者的阴性抗原标记。在3Dpol蛋白中将突变引入跨越H27N31的FMDV A24Cruzeiro的MAb F32-44表位，得到B型牛鼻炎病毒（BRV-2，Y27R31）的同源氨基酸序列。 3B中的突变包括3B1缺失和3B2突变（RQKP-> PVKV，在BRV-2中发现），其消除与MAb F8B的反应性。这些减毒标记病毒为口蹄疫疫苗生产提供了安全的替代方案。疫苗平台包括独特的限制性内切核酸酶位点，可以方便地交换不同FMDV亚型和血清型的衣壳蛋白。生产嵌合病毒以包含远离相关类型A / Turkey / 06或亚洲型FMDV：Asia1-A24LL3BPVKV3DYR和A / Turkey / 06 -A24LL3BPVKV3DYR的衣壳。 A24LL3DYR和A24LL3BPVKV3DYR突变体病毒在牛中没有产生FMD的迹象，也没有产生毒性病毒的脱落。没有观察到疾病或发烧的临床症状，并且在用活A24LL3DYR或嵌合A-Turkey / 06-A24LL3BPVKV3DYR或Asia1-A24LL3BPVKV3DYR病毒接种的猪中未检测到接触动物的传播。用化学灭活的A24LL3DYR和A24LL3BPVKV3DYRvaccine候选物免疫的牛显示出与多价商业FMDV疫苗相当的功效，并保护100％的动物免受亲代病毒攻击。与cELISA一起使用的单和双标记FMDV疫苗候选者为DIVA伴侣测试提供了合适的目标。

3. 发明申请

WO2016073929A1 HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF 审中-公开
标题翻译：手，脚和口袋疫苗及其制造和使用方法
公开(公告)号：WO2016073929A1
公开(公告)日：2016-05-12
申请号：PCT/US2015/059587
申请日：2015-11-06
申请人： TAKEDA VACCINES, INC.
发明人： DAS, Subash, Chandra , SANTANGELO, Joseph, David , STINCHCOMB, Dan Thomas , OSORIO, Jorge, E.
IPC分类号： C12N15/41
CPC分类号： A61K39/125 , A61K39/12 , A61K2039/5252 , A61K2039/545 , A61K2039/55505 , A61K2039/575 , A61K2039/70 , C12N7/00 , C12N2770/00052 , C12N2770/32134 , C12N2770/32152 , C12N2770/32171 , C12N2770/32334 , C12N2770/32363 , C12N2770/32371 , Y02A50/466
摘要： The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof. Thus, there is a need to develop vaccines and immunogenic compositions for treating and/or preventing hand, food, and mouth disease, particularly in children. In order to meet this need, the present disclosure provides vaccines and immunogenic compositions for treating and/or preventing hand, foot, and mouth disease that include antigens from at least one virus that causes hand, foot, and mouth disease in humans, such as EV71, CA6, and CA16.
摘要翻译：本公开涉及具有一种或多种来自至少一种在人体中引起手足足口病的病毒的抗原的手足口病疫苗和免疫原性组合物，以及制造，制备和测试方法以及用途它们。因此，需要开发用于治疗和/或预防手，食物和口腔疾病，特别是儿童的疫苗和免疫原性组合物。为了满足这种需要，本公开提供用于治疗和/或预防手足口病的疫苗和免疫原性组合物，其包括来自至少一种在人类中引起手足足口病的病毒的抗原，例如 EV71，CA6和CA16。

4. 发明申请

WO2012003129A2 DEVELOPMENT OF A MARKER FOOT AND MOUTH DISEASE VIRUS VACCINE CANDIDATE THAT IS ATTENUATED IN THE NATURAL HOST 审中-公开
标题翻译：在天然宿主中降解标记基因和口腔病毒疫苗候选株的研制
公开(公告)号：WO2012003129A2
公开(公告)日：2012-01-05
申请号：PCT/US2011/041567
申请日：2011-06-23
申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE , RIEDER, Aida E. , RODRIGUEZ, Luis L. , HOLLISTER, Jason R. , UDDOWLA, Sabena
发明人： RIEDER, Aida E. , RODRIGUEZ, Luis L. , HOLLISTER, Jason R. , UDDOWLA, Sabena
IPC分类号： C12N15/42 , A61K39/135 , C12N15/86 , C12Q1/70
CPC分类号： C07K14/005 , A61K39/12 , A61K39/135 , A61K2039/5252 , A61K2039/5254 , A61K2039/552 , A61K2039/55566 , C12N7/00 , C12N2770/32121 , C12N2770/32122 , C12N2770/32134 , C12N2770/32151 , C12N2770/32162 , C12N2770/32163 , C12N2770/32171 , C12Q1/701 , G01N33/56983 , G01N2469/10
摘要： We have generated novel molecularly marked FMDV A 24 LL3D YR and A 24 LL3B PVKV 3D YR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3D pol and 3B proteins. Mutations were introduced into MAb F32-44 epitope in FMDV A24Cruzeiro spanning residues H 27 N 31 in 3 Dpol protein to obtain the homologous amino acid sequence of bovine rhinitis virus type B (BRV-2, Y 27 R 31 ). Mutations in 3B consisted of a deletion of 3B 1 and a mutation in 3B 2 (RQKP->PVKV, found in BRV-2) that abolishes reactivity with MAb F8B. These attenuated marker viruses provide safe alternatives for FMD vaccine manufacturing. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. Chimeric viruses were produced to contain the capsid of distantly related type A/Turkey/06 or Asia type FMDV: Asia1-A 24 LL3B PVKV 3D YR and A/Turkey/06 -A 24 LL3B PVKV 3D YR . A2 4 LL3D YR and A 24 LL3B PVKV 3D YR mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A24LL3DYR or the chimeric A-Turkey/06-A 24 LL3B PVKV 3D YR or Asia1-A 24 LL3B PVKV 3D YR viruses. Cattle immunized with chemically inactivated A24LL3DYR and A 24 LL3B PVKV 3D YR vaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine and protected 100% the animals from challenge with parental virus. The single and double marked-FMDV vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.
摘要翻译：我们已经产生了新的分子标记的FMDV A 24 LL3DYYR和A 24 LL3B PVKV， 3D> YR疫苗候选物。突变病毒含有导致病毒在体内减毒的前导编码区（LL）缺失和在病毒非结构3D pol和3B蛋白之一或两者中引入的阴性抗原标志物。将突变导入3'Dpol蛋白中FMDV A24Cruzeiro跨越残基H27N31的MAb F32-44表位中以获得同源氨基酸序列的B型牛鼻炎病毒（BRV-2，Y27R31）。 3B中的突变由3B1的缺失和3B2（RQKP-＆gt; PVKV，在BRV-2中发现）中的突变组成，其消除了与MAb F8B的反应性。这些减毒标记病毒为口蹄疫疫苗制造提供了安全的选择。该疫苗平台包含独特的限制性内切酶位点，以便于更换不同FMDV亚型和血清型的衣壳蛋白。产生嵌合病毒以包含远缘相关的A / Turkey / 06型或亚洲型FMDV的衣壳：Asia1-A24 LL3B-PVKV 3D-YR 和A /土耳其/ 06 -A <24> LL3B YR 。 A2 4 LL3DYYR和A244 LL3B PVKV 3DYR突变体病毒产生无口蹄疫的迹象以及牛群中没有病毒流出。在接种活A24LL3DYR或嵌合A-Turkey / 06-A24 LL3B PVKV的猪中没有观察到疾病或发热的临床体征并且未检测到接触性动物的传播。亚型YR亚型或Asia1-A24型LL3B亚型PVKV 3DYR亚型病毒。用化学灭活的A24LL3DYR和A24LL3BVVKV 3DYR候选疫苗候选物免疫接种的牛表现出与多价商业FMDV疫苗相当的功效并且保护了100％来自亲代病毒攻击的动物。与cELISA结合使用的单标记和双标记FMDV候选疫苗为DIVA伴侣测试提供了合适的目标。

5. 发明申请

WO2017091418A1 FMDV AND E2 FUSION PROTEINS AND USES THEREOF 审中-公开
标题翻译： FMDV和E2融合蛋白及其用途
公开(公告)号：WO2017091418A1
公开(公告)日：2017-06-01
申请号：PCT/US2016/062367
申请日：2016-11-16
申请人： MERIAL, INC.
发明人： AUDONNET, Jean-christophe , REYNARD, Frederic , BOMCHIL, Natalia , SIGOILLOT-CLAUDE, Cecile
IPC分类号： A61K39/135 , C07K14/32 , A61K39/00
CPC分类号： A61K39/135 , A61K39/385 , A61K2039/5258 , A61K2039/545 , A61K2039/552 , A61K2039/55566 , A61K2039/6075 , C07K14/005 , C07K14/32 , C07K2319/40 , C07K2319/735 , C12N7/00 , C12N2770/24222 , C12N2770/32122 , C12N2770/32134 , C12N2770/32171
摘要： The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV. The invention further encompasses methods of making or producing antigenic polypeptides or antigens.
摘要翻译：本发明包括FMDV疫苗或组合物。疫苗或组合物可以是含有FMDV抗原的疫苗或组合物。本发明还包括编码和表达FMDV抗原，表位或免疫原的重组载体，所述FMDV抗原，表位或免疫原可用于保护动物，特别是绵羊，牛，猫或猪免受FMDV的损害。本发明还包括制造或生产抗原性多肽或抗原的方法。

6. 发明申请

WO2007059461A2 ADENOVIRAL VECTOR-BASED FOOT-AND-MOUTH DISEASE VACCINE 审中-公开
标题翻译：基于腺病毒的基于矢量和口腔疾病的疫苗
公开(公告)号：WO2007059461A2
公开(公告)日：2007-05-24
申请号：PCT/US2006/060830
申请日：2006-11-13
申请人： GENVEC, INC. , BROUGH, Douglas, E. , BRUDER, Joseph, T. , KING, C., Richter
发明人： BROUGH, Douglas, E. , BRUDER, Joseph, T. , KING, C., Richter
CPC分类号： A61K39/135 , A61K39/12 , A61K2039/5258 , A61K2039/552 , C12N15/86 , C12N2710/10343 , C12N2770/32134 , C12N2770/32171
摘要： The invention is directed to an adenoviral vector comprising at least one nucleic acid sequence encoding an aphthovirus antigen and/or a cytokine operably linked to a promoter. The adenoviral vector is replication-deficient and requires at most complementation of both the E1 region and the E4 region of the adenoviral genome for propagation. The invention also is directed to a method of inducing an immune response in a mammal comprising administering to the mammal a composition comprising the aforementioned adenoviral vector.
摘要翻译：本发明涉及腺病毒载体，其包含至少一个编码与启动子可操作连接的口疮病毒抗原和/或细胞因子的核酸序列。腺病毒载体是复制缺陷型的，并且需要至多互补腺病毒基因组的E1区和E4区用于繁殖。本发明还涉及在哺乳动物中诱导免疫应答的方法，包括给哺乳动物施用包含上述腺病毒载体的组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式